Zynex Inc. (NASDAQ:ZYXI) shares traded -21.35% lower at $9.76 on Wall Street last session.
In accordance with the data, 3 analysts cover Zynex Inc. (NASDAQ:ZYXI). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $28.50 and a low of $18.00, we find $21.00. Given the previous closing price of $12.41, this indicates a potential upside of 69.22 percent. ZYXI stock price is now -30.43% away from the 50-day moving average and -9.29% away from the 200-day moving average. The market capitalization of the company currently stands at $363.27M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
It has been rated a hold by 0 analysts and a buy by 3. Brokers who have rated the stock have averaged $22.50 as their price target over the next twelve months.
With the price target enhanced from $10 to $18, Piper Sandler Upgraded its rating from Neutral to Overweight for Zynex Inc. (NASDAQ: ZYXI). On February 28, 2022, B. Riley Securities reiterated its ‘Buy’ rating on the stock by increasing its target price from $15.50 to quote $10, while the B. Riley Securities previously rated the stock as ‘Buy’ on July 16, 2021.
In other news, Lucsok Anna, Chief Operating Officer sold 1,103 shares of the company’s stock on Dec 13. The stock was sold for $15,420 at an average price of $13.98. Upon completion of the transaction, the Chief Operating Officer now directly owns 13,973 shares in the company, valued at $0.14 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 31, Chief Financial Officer MOORHEAD DANIEL J sold 38,126 shares of the business’s stock. A total of $407,186 was realized by selling the stock at an average price of $10.68. This leaves the insider owning 18,405 shares of the company worth $0.18 million. Insiders disposed of 71,414 shares of company stock worth roughly $0.7 million over the past 1 year. A total of 40.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ZYXI stock. A new stake in Zynex Inc. shares was purchased by KENT LAKE CAPITAL LLC during the first quarter worth $501,000. LEGATO CAPITAL MANAGEMENT LLC invested $448,000 in shares of ZYXI during the first quarter. In the first quarter, GUGGENHEIM CAPITAL LLC acquired a new stake in Zynex Inc. valued at approximately $180,000. HANCOCK WHITNEY CORP acquired a new stake in ZYXI for approximately $157,000. TREXQUANT INVESTMENT LP purchased a new stake in ZYXI valued at around $152,000 in the second quarter. In total, there are 188 active investors with 29.70% ownership of the company’s stock.
Zynex Inc. (NASDAQ: ZYXI) opened at $10.52 on Tuesday. During the past 12 months, Zynex Inc. has had a low of $4.97 and a high of $17.25. As of last week, the company has a debt-to-equity ratio of 0.19, a current ratio of 3.40, and a quick ratio of 2.70. The fifty day moving average price for ZYXI is $14.03 and a two-hundred day moving average price translates $10.76 for the stock.
The latest earnings results from Zynex Inc. (NASDAQ: ZYXI) was released for Sep, 2022. According to the Medical Distribution Company, earnings per share came in at $0.13, beating analysts’ expectations of $0.12 by 0.01. This compares to $0.16 EPS in the same period last year. The net profit margin was 12.30% and return on equity was 26.00% for ZYXI. The company reported revenue of $41.52 million for the quarter, compared to $34.79 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 19.36 percent. For the current quarter, analysts expect ZYXI to generate $49.71M in revenue.
Zynex Inc.(ZYXI) Company Profile
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and knee braces for knee support. Further, it offers Zynex Fluid Monitoring System (CM-1500), a fluid volume monitor, which is a non-invasive medical device for monitoring relative fluid volume changes used in operating and recovery rooms to detect fluid loss during surgery and internal bleeding during recovery; Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
